Reclast® (zoledronic acid)

Reclast (zoledronic acid) is covered for FDA‑approved indications (treatment/prevention of osteoporosis in postmenopausal women and men, glucocorticoid‑induced osteoporosis, Paget’s disease) and compendial use for osteogenesis imperfecta; other indications are excluded unless supported by compendial evidence. Approvals require documented diagnosis and specific criteria (for osteoporosis: fragility fracture or T‑score ≤‑2.5 or high‑risk low bone mass) plus usually prior inadequate response, intolerance, or inability to take oral bisphosphonates (often after a 12‑month trial); reauthorization requires demonstrated benefit (stability, reduced vertebral fractures, or increased BMD) with dosing‑interval limits (prevention reauth also requires ≥24 months since the last dose), and Paget/OI require relevant lab/symptom or weight/dosing documentation.

"Treatment of Paget's disease of bone in men and women"